Tumour differentiation (grade) was classified as well differentiated (grade 1), moderately differentiated (grade 2) and poorly differentiated (grade 3).
The prostate cancer grading (as provided by the manufacturer US BioMax) was as follows: grade I, well differentiated; grade II, moderately differentiated; grade III, poorly differentiated.
The histology of most of the patients was squamous cell carcinoma (64.9%), mostly with well differentiated grade (67.0%), tumor size T4 (75.3%), nodal status N2 (34.0%) and tumor stage IV (71.1%).
The grading consists of well-differentiated (grade 1), moderately differentiated (grade 2), and poorly differentiated (grade 3) tumors.
Endometrial cancer cells are described as well differentiated, Grade 1 (ECG1), moderately differentiated, Grade 2 (ECG2), or poorly differentiated, Grade 3 (ECG3).
Cases described as 'well differentiated' were assigned grade 1; 'moderately differentiated,' grade 2; 'poorly differentiated,' grade 3 and 'ungraded (including grade Gx and missing data),' grade unknown.
Tumour histological grade was categorized as: grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated; and grade 4, undifferentiated (Compton et al, 2000).
Tumour grade was also assigned based on the UICC criteria, dividing tumours into grade I (well differentiated), grade II (moderately differentiated), and grade III (poorly differentiated).
Where available, the grade of the tumour was coded as grade 1 (well differentiated), grade 2 (moderately differentiated) and grade 3 (poorly differentiated).
Tumor grade was divided into 3 groups: well-differentiated (grade I, 31 cases), moderately differentiated (grade II, 74 cases), and poorly differentiated (grade III-IV, 55 cases).
